Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, Oxford University, Oxford, UK.
Trends Parasitol. 2022 Aug;38(8):673-682. doi: 10.1016/j.pt.2022.05.003. Epub 2022 Jun 7.
African children under 5 years of age bear the main burden of global malaria mortality. Seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ) given monthly during the rainy season is a highly effective malaria intervention for children aged between 3 months and 5 years living in the Sahel region, a region of intense but seasonal malaria transmission. This intervention is now being considered for other regions of Africa where malaria parasites are more drug resistant. Dihydroartemisinin-piperaquine (DP), an artemisinin-based combination therapy (ACT), has proved to be highly effective and well tolerated in intermittent preventive treatment in pregnant women and children. This combination may be a suitable alternative for SMC. Understanding the safety, pharmacokinetic and pharmacodynamic properties of antimalarial combination therapies is crucial in optimising dosing.
五岁以下的非洲儿童承受着全球疟疾死亡的主要负担。在萨赫勒地区，每月在雨季给予磺胺多辛-乙胺嘧啶（SP）加阿莫地喹（AQ）的季节性疟疾化学预防（SMC），是一种针对 3 个月至 5 岁儿童的高效疟疾干预措施，该地区疟疾传播强烈但具有季节性。现在正在考虑将这种干预措施用于疟疾寄生虫耐药性更强的非洲其他地区。二氢青蒿素-哌喹（DP）是一种基于青蒿素的联合疗法（ACT），已被证明在孕妇和儿童间歇性预防治疗中非常有效且耐受良好。这种组合可能是 SMC 的合适替代品。了解抗疟联合疗法的安全性、药代动力学和药效学特性对于优化剂量至关重要。
